

Antibody against TNF

Contents

- 1 Objective
- 2 Background
 - ◆ 2.1 Tumor necrosis factor
 - ◆ 2.2 Anti-TNF antibody
- 3 Search strategy
 - ◆ 3.1 Micropatent full text search
 - ◆ 3.2 Micropatent INPADOC search
 - ◆ 3.3 Eurasian patent office search
 - ◇ 3.3.1 EA@ Eurasian patent office
 - ◇ 3.3.2 RU@ Eurasian patent office
 - ◇ 3.3.3 Russian Keyword Search
- 4 Class codes
 - ◆ 4.1 ECLA class codes
 - ◆ 4.2 IPC class codes
- 5 Patent Search Results
- 6 Important charts
 - ◆ 6.1 Filing year vs number of patents
 - ◆ 6.2 Publication year vs number of patents
 - ◆ 6.3 Calculated expiry year vs number of patents
 - ◆ 6.4 Assignees vs number of patents
 - ◆ 6.5 Summary chart

Objective



Antigen-Antibody binding Source

1. To map the existence and status of pending patent applications and patents filed in Russia (either directly at the Russian patent office or via the Eurasian Patent Office) that are directed at anti-TNF α antibodies, including antibodies such as infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), and golimumab (Simponi), and their uses.

Background

Tumor necrosis factor

Tumor necrosis factor is a cytokine involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute phase reaction. The primary role of TNF is in the regulation of immune cells. TNF is also able to induce apoptotic cell death, to induce inflammation, and to inhibit tumorigenesis and viral replication. Dysregulation of TNF production has been implicated in a variety of human diseases, as well as cancer [Source](#) TNF is critically involved in the pathogenesis of several chronic inflammatory diseases. Monoclonal antibodies against TNF are currently used for the treatment of rheumatoid arthritis and Crohn's disease. [Dalum et al., 1999](#)

Anti-TNF antibody

Monoclonal antibodies to tumor necrosis factor alpha (TNF-alpha) and soluble receptor complexes comprising the extramembrane portion of the TNF receptor coupled with the Fc portion of the human IgG1 molecule have been utilized as therapies for severe sepsis and septic shock. [Abraham, 2004 A](#) review about TNF- α , based on 78 published articles, using TNF- α antibody is [summarized here](#)

Since tumor necrosis factor (TNF) plays an important role in host defense and tumor growth control. Therefore, anti-TNF antibody therapies may increase the risk of serious infections and malignancies. To assess the extent to which anti-TNF antibody therapies may increase the risk of serious infections and malignancies in patients with rheumatoid arthritis a study has been conducted by [Bongartz et al., 2006](#)

Search strategy

To capture the Russian patents a 3 way search strategy was built:

- Micropatent full text searches on English patents and then taking out Russian family members from the on target English patents
- Searching patents with keywords and class codes having country code RU (Russia) and EA (Eurasia) in Micropatent INPADOC
- Searching for patents in Eurasian patent office and Russian patent office, individually, with class codes and keywords

Micropatent full text search

Search logic: To first search for all English patents (such as US, WO, EP etc.) with keywords given below and then filter out patents which have Russian family members.

- Database: Micropatent-Full text

Issue/Publication date: <=20100405

Sr. No.	Search concept	Keywords	Hits
1	Keywords based search	((Antibod* OR (Anti ADJ1 bod*) OR Immunoglobulin*1 OR (Immuno ADJ1 globulin*1) OR MAB OR MABS OR Infliximab OR Remicade OR adalimumab OR Humira OR certolizumab OR pegol OR Cimzia OR golimumab OR Simponi) AND (((Tumour OR Tumor) ADJ2 (necros*2) ADJ2 (factor*1)) OR *TNF OR TNF* OR cachexin OR cachectin))	9861 hits
2	Key assignee with TNF keywords	Assignee/Applicant: Centocor OR (Johnson ADJ2 Johnson) OR (Mitsubishi ADJ1 Tanabe ADJ1 Pharma*) OR (Xian ADJ1 Janssen) OR (Schering-Plough) OR Abbott OR (BASF ADJ1 Knoll) OR (Cambridge ADJ1 Antibody ADJ1 Technology) OR Medimmune OR (UCB ADJ1 Pharma) AND Keywords in Claims, Title and Abstract: TNF* OR (Tumour ADJ2 Necrosis ADJ2 factor*) OR *TNF OR (Tumor ADJ2 Necrosis ADJ2 factor*)	517 hits
3	Key assignee with drug names	Assignee/Applicant: Centocor OR (Johnson ADJ2 Johnson) OR (Mitsubishi ADJ1 Tanabe ADJ1 Pharma*) OR (Xian ADJ1 Janssen) OR (Schering-Plough) OR Abbott OR (BASF ADJ1 Knoll) OR (Cambridge ADJ1 Antibody ADJ1 Technology) OR Medimmune OR (UCB ADJ1 Pharma) AND Keywords in Claims, Title and Abstract: Simponi OR Remicade OR Humira OR Cimzia	10
4	Class based search	ECLA: C07K0014525 OR C07K0014705Q OR C07K0014705R OR C07K0014715B OR C07K001628Q OR C07K001628R OR C07K01624B OR A61K003819A Any classification: C070014525 OR C12N001528	293 hits
Final		1 OR 2 OR 3 OR 4	10190 patents (3772 unique records) (337 records having RU/EA family member)

Micropatent INPADOC search

Search logic: Micropatent-INPADOC search bibliographic data for 71 countries and legal status for 42. A search strategy based out of keywords and classes was built to search patents having country code RU (Russia) and EA (Eurasia) in Micropatent INPADOC

- Issue/Publication date: <=20100405

Sr. No.	Search concept	Keywords	Hits
1	Keywords based search	((Antibod* OR (Anti ADJ1 bod*) OR Immunoglobulin*1 OR (Immuno ADJ1 globulin*1) OR MAB OR MABS OR Infliximab OR Remicade OR adalimumab OR Humira OR certolizumab OR pegol OR Cimzia OR golimumab OR Simponi) AND (((Tumour OR Tumor) ADJ2 (necros*2) ADJ2 (factor*1)) OR *TNF OR TNF* OR cachexin OR cachectin))	48 hits
2	ECLA classes specific for Anti-TNF antibody	C07K01628Q OR C07501628R OR C07K01624B	51 hits
3	ECLA classes specific for TNF with Antibody keywords	A61k03819A OR C07K014525 OR C07K014705Q OR C07K014705R OR C07K014715B AND ((Antibod* OR (Anti ADJ1 bod*) OR Immunoglobulin*1 OR (Immuno ADJ1 globulin*1) OR MAB OR MABS) OR Infliximab OR Remicade OR adalimumab OR Humira OR certolizumab OR pegol OR Cimzia OR golimumab OR Simponi)	28 hits
4	IPC classes specific for TNF with Antibody keywords	C07014525 OR C12N01528 AND ((Antibod* OR (Anti ADJ1 bod*) OR Immunoglobulin*1 OR (Immuno ADJ1 globulin*1) OR MAB OR MABS) OR Infliximab OR Remicade OR adalimumab OR Humira OR certolizumab OR pegol OR Cimzia OR golimumab OR Simponi)	5 hits
5		1 OR 2 OR 3 OR 4	100 Hits (87 unique records)

Eurasian patent office search

Search Logic: Eurasian patent office allows searching in Russian and Eurasian patent databases. Search was performed based on keywords and class codes as shown below.

EA@ Eurasian patent office

- All the records were analyzed

Sr. No.	Search concept	Keywords	Hits
1	Keywords based search	(Tumor* AND Factor*) OR TNF*	11
2	Specific class based search	IPC: C07K14/525 OR C12N15/28	3
3	Broad class based search	IPC: A61K38/19 OR C07K14/705 OR C07K14/715 OR C07K16/28 OR C07K16/24	34

RU@ Eurasian patent office

- All the records were analyzed

Sr. No.	Search concept	Keywords	Hits
1	Keywords based search	(Tumor* AND Factor*) OR TNF*	52
2	Specific class based search	IPC: C07K14/525 OR C12N15/28	11
3	Broad class based search	IPC: A61K38/19 OR C07K14/705 OR C07K14/715 OR C07K16/28 OR C07K16/24	174

Russian Keyword Search

- Russian technical keywords were searched & identified from the relevant Russian patent document and confirmed with the corresponding English patent document and verified with the google translator.
- Eurasian Patent Office allows to search both in the English language and Russian language.

S.No	Russian Keywords	English Keywords
1	???	TNF
2	???-alpha	TNF-alpha
3	?????? ??????? ????????	tumor necrosis factor
4	????-TNF ?????	anti-TNF alpha
5	????-TNF	anti-TNF
6	TNF ?????	TNF alpha

Class codes

ECLA class codes

Sr. No.	Class code	Definition
1	A61k03819A	Medicinal preparations containing peptides - Tumor necrosis factor
2	C07K014525	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Tumor necrosis factor (TNF)
3	C07K014705Q	Peptides having more than 20 amino acids - NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48 , TNF C07K14/525) [N9706]
4	C07K014705R	Peptides having more than 20 amino acids - NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
5	C07K014715B	Peptides having more than 20 amino acids - for tumor necrosis factor (TNF), for lymphotoxin
6	C07K01628Q	Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies - against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22 , against TNF C07K16/24B) [N9703] [C9705]
7	C07501628R	Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies - against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 [N9702] [C0406]

8	C07K01624B	Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies - Tumor Necrosis Factors
---	------------	--

IPC class codes

Sr. No.	Class code	Definition
1	C07K14/525	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Tumour necrosis factor (TNF)
2	C12N15/28	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor - Tumor necrosis factors

Patent Search Results

- [Click here](#) to download **updated** relevant patents with legal status, filtering option and hyperlinking.

NOTE: Legal status of the Russian patent applications and publications was retrieved from ROSPATENTS wherever available. Legal Status can also be retrieved from STN - INPADOCDB & RUSSIAPAT databases.

Legal Status coverage -Timeline	
STN- INPADOCDB	1978 to Present
STN- RUSSIAPAT	1994 to Present
Micropat- INPADOC	1920 to Present

- **STN databases price list**

Database	Connect hour	Display Record
STN- INPADOCDB	232 \$ per Hour	1.24 \$ per Record
STN- RUSSIAPAT	186 \$ per Hour	2.28 \$ per Record

- **Legal status display format in the STN - INPADOCDB, RUSSIAPAT databases**

LEGAL STATUS

AN 24180089 INPADOCDB

20041222 EPAK + DESIGNATED CONTRACTING STATES:
 EP A1
 AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU
 MC NL PL PT RO SE SI SK TR

20041222 EPAX + EXTENSION OF THE EUROPEAN PATENT TO
 AL HR LT LV MK

20050803 EP17P + REQUEST FOR EXAMINATION FILED
 20050603
 EXA Examination, Search Report

20050914 EPAKX + PAYMENT OF DESIGNATION FEES
 DE FR GB

20061004 EPAK + DESIGNATED CONTRACTING STATES:
 EP B1
 DE FR GB

20061004 EPREG
 GBFG4D + REFERENCE TO A NATIONAL CODE
 + GB: EUROPEAN PATENT GRANTED
 200641

20061116 EPREF CORRESPONDS TO:
 DE 602004002620 P 20061116
 200646

20070314 EPRAP2 PATENT OWNER REASSIGNMENT (CORRECTION)
 FUJIFILM CORPORATION
 CHG Change of Owner, Inventor, Applicant
 200711.....20070315

20070411 EPREG
 GB732E + REFERENCE TO A NATIONAL CODE
 GB: PROCEEDING UNDER SECTION 32 PATENTS ACT 1977
 CHG Change of Owner, Inventor, Applicant
 200716.....20070419

20070420 EPET + FR: TRANSLATION FILED
 200719.....20070510



Legal status display format

```


LEGAL STATUS
AN 24180089 INPADOCDB
20041222 EPAK + DESIGNATED CONTRACTING STATES:
                EP A1
                AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU
                MC NL PL PT RO SE SI SK TR
20041222 EPAX + EXTENSION OF THE EUROPEAN PATENT TO
                AL HR LT LV MK
20050803 EP17P + REQUEST FOR EXAMINATION FILED
                20050603
                EXA Examination, Search Report
20050914 EPAKX + PAYMENT OF DESIGNATION FEES
                DE FR GB
20061004 EPAK + DESIGNATED CONTRACTING STATES:
                EP B1
                DE FR GB
20061004 EPREG REFERENCE TO A NATIONAL CODE
                GBFG4D + GB: EUROPEAN PATENT GRANTED
                200641
20061116 EPREF CORRESPONDS TO:
                DE 602004002620 P 20061116
                200646
20070314 EPRAP2 PATENT OWNER REASSIGNMENT (CORRECTION)
                FUJIFILM CORPORATION
                CHG Change of Owner, Inventor, Applicant
                200711.....20070315
20070411 EPREG REFERENCE TO A NATIONAL CODE
                GB732E GB: PROCEEDING UNDER SECTION 32 PATENTS ACT 1977
                CHG Change of Owner, Inventor, Applicant
                200716.....20070419
20070420 EPET + FR: TRANSLATION FILED
                200719.....20070510

```

Legal status display format

Important charts


Filing year vs number of patents






Filling year vs number of patents

Publication year vs number of patents



Publication year vs number of patents


Calculated expiry year vs number of patents



Calculated expiry year vs number of patents


Assignees vs number of patents

Assignee VS No.of Patents



Assignees vs number of patents
Summary chart

Summary Legal status of patents as on 8.04.2010



Summary chart